retatrutide status fda Before Approval: What Nurses Need to Know ⚠️ BEWARE OF RETATRUTIDE SOLD

Phase 2 trial data published in the New England Journal of Medicine in 2023 generated considerable interest, though retatrutide has not yet received MHRA or EMA marketing authorisation and remains unavailable through NHS or regulated private prescribing pathways

Reported side effects are similar to other GLP-1 type drugs mainly mild to moderate gastrointestinal symptoms like nausea or diarrhea, especially during dose escalation

Normal serum potassium ranges from 3.55.0 mEq/L

Is Tirzepatide available in Canada for research

But in the best way

Individual informed consent for participation in the current study was waived since subject information is deidentified and specific patients cannot be identified